Home/Filings/4/0000950170-25-082306
4//SEC Filing

Graham G. Walmsley 4

Accession 0000950170-25-082306

CIK 0001744659other

Filed

Jun 4, 8:00 PM ET

Accepted

Jun 5, 4:05 PM ET

Size

6.3 KB

Accession

0000950170-25-082306

Insider Transaction Report

Form 4
Period: 2025-06-03
Transactions
  • Award

    Common Stock

    2025-06-03+9,39811,566 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    1,200,000
Footnotes (2)
  • [F1]These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board.
  • [F2]The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Documents

1 file

Issuer

Akero Therapeutics, Inc.

CIK 0001744659

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001777517

Filing Metadata

Form type
4
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 4:05 PM ET
Size
6.3 KB